SHINE submits Drug Master File for n.c.a. Lu-177
![](/file/7024/SHINE-Box_Mockups_Stacked_3-Front-Logo-no-back 2x1.jpg)
SHINE Technologies, the Janesville, Wis.–based producer of medical radioisotopes, announced that it has submitted a drug master file (DMF) with the U.S. Food and Drug Administration for non-carrier-added (n.c.a.) lutetium-177 chloride, a radiopharmaceutical used for the treatment of cancer.